Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MKlp2-mitosis

Financiado

Cerrado

MKlp2 a mitotic kinesin and a prime target for cancer therapy

Mklp2, a mitotic kinesin and a prime target for cancer therapy MKlp2 belongs to kinesin 6 family and was first identified as an effector protein of small G protein Rab6A, involving in the retrograde transport between Golgi and ER... ver más

31/10/2015

INSTITUT CURIE FON...

261K€

Presupuesto del proyecto: 261K€

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-10-31 No tenemos la información de la convocatoria

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

INSTITUT CURIE FONDATION

0.00€ | Lider

Proyectos interesantes

SAF2012-38215

Medical Technol...

Applied Physics

468K€ Cerrado

Mastl CDC

Medical Technol...

Applied Physics

227K€ Cerrado

MITDYN

Medical Technol...

Applied Physics

100K€ Cerrado

BFU2008-04293

Medical Technol...

Applied Physics

91K€ Cerrado

PID2021-127045NB-I00

Medical Technol...

Applied Physics

133K€ Cerrado

PRECISE

Medical Technol...

Applied Physics

1M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

INSTITUT CURIE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 261K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Mklp2, a mitotic kinesin and a prime target for cancer therapy MKlp2 belongs to kinesin 6 family and was first identified as an effector protein of small G protein Rab6A, involving in the retrograde transport between Golgi and ER. While its function in Golgi-ER trafficking awaits further study, MKlp2 has been shown to play crucial role in mitosis. It is essential to relocate chromosomal passenger protein Aurora B and the mitotic regulator Plk1 to the central spindle during anaphase. Depletion of MKlp2 results in failure of cytokinesis. In addition, MKlp2 is overexpressed in several human tumor cells and inhibition of MKlp2 reduces the tumor cell growth. Those properties make MKlp2 a prime target for developing anti cancer drugs. MKlp2 has been shown to interact directly to Plk1 and Mad2, the mitotic checkpoint complex protein. However, the mechanism of MKlp2 motor protein and how those interactions may regulate its function is unknown. In addition, MKlp2 possess unique sequences in its motor domain compared to other kinesins which may render its mechanism of nucleotide/microtubule binding. To understand how MKlp2 functions and how it’s regulated during mitosis, we propose a thorough functional and structural characterization of this interesting motor protein. Aim1. Functional and structural characterization of the motor domain of MKlp2, the kinesin involves in cytokinesis and a potential target for anti-cancer drugs Aim2. To study in detail the interaction between MKlp2 and Plk1, its regulation of the function of MKlp2, and to determine the structure of the complex Aim3. To characterize the interaction between MKlp2 tail domain and Mad2, the structure of the complex, and the role of the interaction in cytokinesis Our results from this multidisciplinary proposal will provide valuable information on the mechanism of MKlp2, further our understanding on kinesin motors, and allow development of anti-cancer drugs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores